<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02400164</url>
  </required_header>
  <id_info>
    <org_study_id>2013-AAR-007</org_study_id>
    <nct_id>NCT02400164</nct_id>
  </id_info>
  <brief_title>A (M)Ulti-center, Prospective, (O)Pen Label, Uncontrolled Feasibility (S)Tudy to Assess the Safety and Effectiveness of an Automatic Low Flow (A)Scites (Alfa) Pump (I)n Patients With (C)Irrhosis and Refractory or Recurrent Ascites</brief_title>
  <acronym>MOSAIC</acronym>
  <official_title>A (M)Ulti-center, Prospective, (O)Pen Label, Uncontrolled Feasibility (S)Tudy to Assess the Safety and Effectiveness of an Automatic Low Flow (A)Scites (Alfa) Pump (I)n Patients With (C)Irrhosis and Refractory or Recurrent Ascites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sequana Medical N.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sequana Medical N.V.</source>
  <brief_summary>
    <textblock>
      The study is a multi-center, prospective, open label, uncontrolled feasibility study&#xD;
      enrolling 30 patients with refractory or recurrent ascites and cirrhosis at up to 6 sites.&#xD;
      Patients will be enrolled during a 6 month enrollment phase after which data will be&#xD;
      collected for 12months with an initial analysis after 3 months. Extended follow-up for safety&#xD;
      monitoring purposes will continue for the lifetime of the patient or until the device is&#xD;
      explanted.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">March 31, 2018</completion_date>
  <primary_completion_date type="Actual">January 19, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of serious adverse events related to the device and its implantation.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the overall requirement for large volume paracentesis</measure>
    <time_frame>12 months</time_frame>
    <description>Assess the overall requirement for large volume paracentesis by investigation of:&#xD;
the number of large volume therapeutic paracentesis events and all paracentesis events&#xD;
the annualized rate of large volume therapeutic paracentesis and of all paracentesis events&#xD;
the cumulative volume of ascites removed through all paracentesis events&#xD;
• Assess the overall requirement for large volume paracentesis by investigation of:&#xD;
the number of large volume therapeutic paracentesis events and all paracentesis events&#xD;
the annualized rate of large volume therapeutic paracentesis and of all paracentesis events&#xD;
the cumulative volume of ascites removed through all paracentesis events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>12 months</time_frame>
    <description>Nutritional status&#xD;
o evaluate changes in serum prealbumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate patient quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate patient quality of life&#xD;
chronic liver disease questionnaire (CLDQ)&#xD;
PLD questionnaire&#xD;
ECOG performance status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Ascites</condition>
  <arm_group>
    <arm_group_label>alfapump system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Sequana Medical alfapump system is an implanted subcutaneous device with a rechargeable battery that moves ascitic fluid from the peritoneal cavity to the urinary bladder where it is eliminated by spontaneous diuresis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>alfapump system</intervention_name>
    <description>The Sequana Medical alfapump system is an implanted subcutaneous device with a rechargeable battery that moves ascitic fluid from the peritoneal cavity to the urinary bladder where it is eliminated by spontaneous diuresis.</description>
    <arm_group_label>alfapump system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. patients ≥ 21 years of age&#xD;
&#xD;
          2. recurrence of grade 3 ascites requiring paracentesis for symptom relief more&#xD;
             frequently than once per month for a minimum of 2 of the prior 3 months&#xD;
&#xD;
          3. cirrhosis of any etiology&#xD;
&#xD;
          4. failure to respond to or intolerance to high dose diuretics&#xD;
&#xD;
          5. expected survival of greater than 3 months (MELD score ≤ 21)&#xD;
&#xD;
          6. screened for varices and on optimal management&#xD;
&#xD;
          7. diagnostic paracentesis with neutrophil count &lt; 250 / µl within 24 hours of&#xD;
             implantation&#xD;
&#xD;
          8. written informed consent&#xD;
&#xD;
          9. ability to comply with study procedures and ability to operate the device&#xD;
&#xD;
         10. women of childbearing potential should use adequate contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. more than 2 systemic or local infections, such as peritonitis, urinary tract&#xD;
             infection, or abdominal skin infection within the last 6 months&#xD;
&#xD;
          2. presence of any current cancer&#xD;
&#xD;
          3. evidence of extensive ascites loculation&#xD;
&#xD;
          4. serum creatinine &gt; 1.5 mg/dl&#xD;
&#xD;
          5. serum bilirubin &gt; 5 mg/dl&#xD;
&#xD;
          6. eGFR &lt; 30 ml/min/1.73m2 by MDRD (Modification of Diet in Renal Disease) method&#xD;
&#xD;
          7. gastrointestinal hemorrhage due to portal hypertension in the 2 weeks prior to&#xD;
             inclusion in the study&#xD;
&#xD;
          8. hepatic encephalopathy &gt; stage II in the two weeks prior to implant&#xD;
&#xD;
          9. presence of a patent TIPS or surgical portosystemic shunt&#xD;
&#xD;
         10. presence of Budd-Chiari syndrome&#xD;
&#xD;
         11. previous solid organ transplant&#xD;
&#xD;
         12. obstructive uropathy (bladder residual volume &gt; 100ml (determined by catheterization&#xD;
             or abdominal ultrasound) or any bladder anomaly which may contraindicate implantation&#xD;
             of the alfapump, including recurrent urinary tract infections, vesicoureteral reflux,&#xD;
             or history of urinary calculi)&#xD;
&#xD;
         13. International Prostate Symptom Score (I-PSS) ≥20&#xD;
&#xD;
         14. thrombocytopenia &lt; 45,000 X106/l&#xD;
&#xD;
         15. patient undergoing therapeutic anticoagulation&#xD;
&#xD;
         16. recent (&lt;4 months) intra-abdominal foreign body or abdominal surgery, diaphragmatic&#xD;
             hernia, abdominal surgery, severe abdominal adhesions, surgically irreparable hernia,&#xD;
             abdominal wall or skin infection, or severe malnutrition.&#xD;
&#xD;
         17. history (&gt;6 months) of diaphragmatic hernia, history of bladder cancer, inflammatory&#xD;
             or ischemic bowel disease, and frequent episodes of diverticulitis.&#xD;
&#xD;
         18. any non-liver disease with life expectancy &lt; 1 year&#xD;
&#xD;
         19. patients eligible for TIPS (unless they have refused TIPS placement).&#xD;
&#xD;
         20. presence of any active implantable or body-worn devices that cannot be removed&#xD;
&#xD;
         21. pregnancy&#xD;
&#xD;
         22. patients being in another therapeutic clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Kamath, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic, Rochester, MN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Pacific Medical</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Healthcare System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VCU Medical Centre</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

